Debbie van Baarle

Both ageing and frailty status impact vaccine-induced transcriptomic profiles and subsequent humoral immunity: results from the VITAL cohort

Manas Joshi, Christophe Carré, Alper Çevirgel, Elske Bijvank et autres

ABSTRACT Vaccine responses vary across individuals due to differences in ageing and health status. Using transcriptomic profiling, we analyzed early gene expression profiles after influenza (QIV) followed by pneumococcal (PCV13) vaccination in 148 participants spanning young, middle-aged, and older adults. The two …

nl, fr, be (code pays fourni par la source)

OMIP: 25-marker flow cytometry panel for broad immunophenotyping of major myeloid and lymphoid cell subsets in fresh human whole blood

Tamara M. J. Brouwers, Martijn W. Vos, Debbie van Baarle, Jolanda Brummelman

OMIP-related data files

nl (code pays fourni par la source)

TRECing down the source: naive and memory T cell generation in dirty mice and men

Lyanne Y. Derksen, Elena de Dios Panal, Tamara M. J. Brouwers, Erdem Şanal et autres

Healthy aging relies on the maintenance of a diverse T cell pool. This diversity is ensured by balancing thymic output, differentiation of naive into memory T cells, T cell proliferation and cell death. For naive T cells, the balance of these processes …

nl, de (code pays fourni par la source)

Morning influenza vaccination elicits superior antigen-specific immune responses in adults aged 60-85 years 2256881

Tamara Brouwers, Koen Vink, Martijn Vos, Harry van Dijken et autres

Abstract Introduction Increasing evidence suggests that timing of vaccine administration affects immune responses, with some studies indicating that morning influenza vaccination (9:00-11:00) elicits a stronger antibody response than afternoon vaccination (15:00-17:00) in older adults. Existing trials focused on antibody responses, but did …

nl (code pays fourni par la source)

Optimal vaccination in aging populations under age-dependent infection fatality risks

Michiel van Boven, Christiaan van Dorp, Maikel M. Bosschaert, Jurjen van der Schans et autres

Abstract Background Vaccination programs have greatly reduced the burden of infectious diseases, particularly in childhood. As populations age, however, the burden of respiratory infections such as influenza A, respiratory syncytial virus (RSV), and SARS-CoV-2 increasingly falls on older adults. Because infection fatality …

nl, us (code pays fourni par la source)

Repurposing Candidate Drugs to Prevent SARS-CoV-2: A PharmLines Test-Negative Case–Control Study

Guiling Zhou, Nina Dael, Stefan Verweij, Spyros Balafas et autres

Background: The rapid emergence of immune-evasive SARS-CoV-2 variants necessitates the identification of accessible, low-cost prophylactic strategies. While drug repurposing offers a time-efficient alternative to novel drug development, clinical evidence for existing medications in the general population remains limited. The PharmLines Initiative provided …

nl (code pays fourni par la source)

Kidney Transplant Recipients Develop Nasal Mucosal Antibodies to SARS‐CoV‐2 With ACE2‐Inhibiting Activity Following mRNA Vaccination

Vera Koomen, Christa E. Gaast-deJongh, Fred van Opzeeland, Ria H.L.A. Philipsen et autres

ABSTRACT Background Less than 60% of kidney transplant recipients (KTRs) become IgG seropositive for the viral spike (S) antigen following two COVID‐19 vaccine doses, with a third dose increasing these numbers further. Mucosal antibodies play a critical role in protection against SARS‐CoV‐2 …

nl (code pays fourni par la source)

COVID-19 boosters restore virus-specific immune responses in kidney transplant recipients unresponsive to primary vaccination

Yvette den Hartog, Yannick van Sleen, Lennert Gommers, Luca M. Zaeck et autres

Kidney transplant recipients (KTRs) often exhibit impaired immune responses to vaccination, necessitating multiple doses to obtain sufficient protection from severe disease. This study compared immunological mechanisms underlying the vaccine-induced response between KTRs who responded to primary vaccination (primary responders) and those who …

nl (code pays fourni par la source)

Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccination

Daryl Geers, Muriel Aguilar-Bretones, Luca M. Zaeck, Paul A. Gill et autres

OBJECTIVES: Ongoing escape from pre-existing antibodies by severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) necessitates yearly coronavirus disease 2019 (COVID-19) vaccine updates. Monovalent variant-specific booster vaccines for at-risk populations aim to re-direct antibody responses towards antigenically distinct variants. However, multiple past exposures …

nl, au (code pays fourni par la source)

Activation phenotypes defined by the coordinated expression of activation markers discriminate TCR-mediated and bystander T cell responses

Tamara J.C. Schenk, Martijn W. Vos, Yannick van Sleen, Debbie van Baarle et autres

T cells, and defined activation phenotypes that distinguish TCR-activated from bystander-activated T cells. In anti-viral responses, peptide stimulation mainly induced bystander activation, yet bystander T cells contributed minimally to cytokine production. Our findings provide a framework for identifying T cell response types …

nl (code pays fourni par la source)

Influenza vaccine-specific T cell responses are impaired in older adults

Pauline Saint-Charles, Magdalena Hagen, Gaëlle Autaa, Elske Bijvank et autres

fr, at, nl (code pays fourni par la source)

Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccination

Daryl Geers, Muriel Aguilar-Bretones, Luca M. Zaeck, Paul A. Gill et autres

Abstract Ongoing escape from pre-existing antibodies by severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) necessitates yearly coronavirus disease 2019 (COVID-19) vaccine updates for at-risk populations. Monovalent variant-specific booster vaccines, such as those for XBB.1.5, JN.1, and LP.8.1, aim to re-direct immune responses …

nl, au (code pays fourni par la source)